{"hands_on_practices": [{"introduction": "The ethical evaluation of CRISPR-Cas9 begins at the molecular level, with the fundamental trade-off between desired precision and inherent risk. This exercise translates the biochemical outcomes of gene editing—successful homology-directed repair versus error-prone non-homologous end joining—into a quantitative ethical framework. By calculating a harm-to-benefit ratio, you will practice how to establish a clear decision-making threshold based on empirical laboratory data, directly linking molecular efficiency to the principles of beneficence and non-maleficence [@problem_id:4858160].", "problem": "A research team is preparing an ex vivo edit of human T cells using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated protein 9 (CRISPR-Cas9) to introduce a precise knock-in at a single locus. After delivering a donor template and the nuclease, they empirically observe the following repair pathway probabilities at the target site per double-strand break: homology-directed repair (HDR) occurs with probability $p_{\\mathrm{HDR}} = 0.15$, non-homologous end joining (NHEJ) occurs with probability $p_{\\mathrm{NHEJ}} = 0.70$, and other outcomes (such as microhomology-mediated end joining or no stable edit) occur with probability $0.15$. Within NHEJ outcomes, frameshift mutations occur with conditional probability $f = 0.20$ and are considered deleterious on-target outcomes for T cell function.\n\nUsing the following fundamental bases:\n- The Central Dogma of molecular biology (deoxyribonucleic acid to ribonucleic acid to protein) motivates why frameshift mutations at coding loci are commonly deleterious, and precise HDR edits are commonly beneficial when they achieve the intended therapeutic modification.\n- The expected value principle from probability theory and standard risk-benefit analysis in medical ethics (beneficence and non-maleficence) model net ethical value per edit as the difference between expected benefits and expected harms, namely $U = w_{b} \\, p_{\\mathrm{precise}} - w_{h} \\, p_{\\mathrm{deleterious}}$, where $w_{b} > 0$ is the ethical weight per precise beneficial edit and $w_{h} > 0$ is the ethical weight per deleterious on-target outcome.\n\nDefine the precise edit fraction as $p_{\\mathrm{precise}} = p_{\\mathrm{HDR}}$ and the deleterious on-target fraction as $p_{\\mathrm{deleterious}} = p_{\\mathrm{NHEJ}} \\times f$. An ex vivo protocol is ethically acceptable under this model if $U \\ge 0$.\n\nCompute the harm-to-benefit weight ratio threshold $\\rho^{\\ast} = \\frac{w_{h}}{w_{b}}$ at which $U = 0$ given the observed probabilities. Express $\\rho^{\\ast}$ as a single real number and round your answer to four significant figures.", "solution": "The scenario specifies repair probabilities at a single locus per double-strand break induced by Clustered Regularly Interspaced Short Palindromic Repeats associated protein 9 (CRISPR-Cas9). The repair pathways include homology-directed repair (HDR), non-homologous end joining (NHEJ), and other outcomes. The question focuses on expected fractions relevant to ethical analysis: the fraction of precise edits and the fraction of deleterious on-target outcomes.\n\nFrom the provided definitions:\n- The fraction of precise edits is the homology-directed repair probability, so\n$$\np_{\\mathrm{precise}} = p_{\\mathrm{HDR}} = 0.15.\n$$\n\n- Deleterious on-target outcomes are frameshift mutations arising under non-homologous end joining. The conditional probability of a frameshift given NHEJ is $f = 0.20$. Therefore, the marginal probability of a deleterious frameshift outcome is\n$$\np_{\\mathrm{deleterious}} = p_{\\mathrm{NHEJ}} \\times f = 0.70 \\times 0.20 = 0.14.\n$$\n\nTo evaluate ethical acceptability, we use the expected value principle consistent with beneficence and non-maleficence:\n$$\nU = w_{b} \\, p_{\\mathrm{precise}} - w_{h} \\, p_{\\mathrm{deleterious}},\n$$\nwhere $w_{b} > 0$ is the ethical weight per precise beneficial edit and $w_{h} > 0$ is the ethical weight per deleterious on-target outcome. Ethical acceptability under this model requires $U \\ge 0$.\n\nWe are asked to compute the harm-to-benefit weight ratio threshold $\\rho^{\\ast} = \\frac{w_{h}}{w_{b}}$ at which $U = 0$. Setting $U = 0$ and solving for $\\rho^{\\ast}$ gives\n$$\n0 = w_{b} \\, p_{\\mathrm{precise}} - w_{h} \\, p_{\\mathrm{deleterious}}\n\\quad \\Longrightarrow \\quad\n\\frac{w_{h}}{w_{b}} = \\frac{p_{\\mathrm{precise}}}{p_{\\mathrm{deleterious}}}.\n$$\nSubstituting the computed probabilities,\n$$\n\\rho^{\\ast} = \\frac{0.15}{0.14} = \\frac{15}{14} \\approx 1.071428571\\ldots\n$$\nRounding to four significant figures, we obtain\n$$\n\\rho^{\\ast} \\approx 1.071.\n$$\n\nInterpreting this threshold within medical ethics: if the institution’s harm weight relative to benefit, $\\frac{w_{h}}{w_{b}}$, exceeds $1.071$, the net expected ethical value $U$ becomes negative, reflecting that the residual risk of deleterious on-target outcomes outweighs the expected benefits of precise edits under these empirical repair probabilities. Conversely, if $\\frac{w_{h}}{w_{b}}$ is less than $1.071$, the ex vivo protocol is ethically acceptable within this expected utility framework. The numerical threshold $\\rho^{\\ast}$ provides a transparent criterion linking the observed molecular outcomes with ethical decision-making grounded in beneficence and non-maleficence.", "answer": "$$\\boxed{1.071}$$", "id": "4858160"}, {"introduction": "Moving from the laboratory to the clinic introduces profound new layers of uncertainty, not just about the technology, but about the genetics of the patient. This practice confronts one of the most common and difficult challenges in modern genomic medicine: the Variant of Uncertain Significance (VUS). Here, you must integrate principles of evidence-based medicine with core ethical tenets to determine when, or if, it is justifiable to use a powerful tool like CRISPR-Cas9, forcing a critical distinction between established therapy and experimental research [@problem_id:4858299].", "problem": "A hospital ethics committee is evaluating a proposal to use CRISPR-Cas9 somatic editing to revert a single-nucleotide change in a cardiomyopathy gene to the reference allele in an adult patient with progressive heart failure. The patient’s genetic test has classified the change as a Variant of Uncertain Significance (VUS). The clinical team argues that animal models of CRISPR-Cas9 delivery suggest low off-target activity and that the disease is severe. The committee must reason from first principles and widely accepted facts: the Central Dogma of molecular biology (deoxyribonucleic acid to ribonucleic acid to protein), the mechanism of CRISPR-Cas9 as a programmable nuclease producing targeted double-strand breaks, established variant classification frameworks such as those from the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP), and the core principles of biomedical ethics (respect for autonomy, beneficence, nonmaleficence, and justice). The committee must also consider requirements for research versus therapy, including oversight by an Institutional Review Board (IRB), clinical equipoise, and the distinction between germline and somatic interventions.\n\nWhich option best integrates a correct definition of a VUS, correctly differentiates a pathogenic variant from a likely pathogenic variant under established classification logic, and derives ethically sound constraints on whether and how CRISPR-Cas9 may be used to edit a VUS in the clinical (non-research) context?\n\nA. A Variant of Uncertain Significance (VUS) is a genetic change with insufficient and conflicting evidence to classify as either benign or pathogenic. A pathogenic variant has sufficient, convergent evidence of causality for disease, whereas a likely pathogenic variant has strong but not definitive evidence, often corresponding to an estimated posterior probability of pathogenicity greater than $90\\%$ under American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) logic. Ethically, editing a VUS as clinical care fails nonmaleficence and beneficence because causal benefit is uncertain and risks from intervention are real; such interventions should proceed only under a research protocol with Institutional Review Board (IRB) oversight, clinical equipoise, rigorous preclinical evidence, and robust informed consent, and should avoid germline editing. In clinical care, somatic CRISPR-Cas9 targeting a VUS is not justified without reclassification to at least likely pathogenic and a favorable risk–benefit profile.\n\nB. A Variant of Uncertain Significance (VUS) is a change that is probably benign, and a likely pathogenic variant is equivalent to a pathogenic variant for clinical decision-making. Because the disease is severe and the patient consents, beneficence and autonomy together justify CRISPR-Cas9 editing of the VUS in routine clinical care without IRB oversight, since off-target risk appears low in animals.\n\nC. A Variant of Uncertain Significance (VUS) is any novel change in a gene plausibly related to a phenotype. Pathogenic and likely pathogenic variants are distinguished by whether the gene is associated with severe disease. In severe disease, beneficence outweighs nonmaleficence, so somatic CRISPR-Cas9 editing of a VUS is ethically permitted if the target gene has a known role in the pathway, regardless of variant-level evidence.\n\nD. A Variant of Uncertain Significance (VUS) is a change that lacks any link to disease but can be treated as likely pathogenic if off-target risks are minimized. Likely pathogenic and pathogenic variants do not meaningfully differ; therefore, editing a VUS is ethically acceptable in clinical care if sequencing depth is high and predicted off-target sites are few.\n\nE. A Variant of Uncertain Significance (VUS) is a genetic change that is uncertain only because the phenotype is mild. Editing a VUS is ethically acceptable in somatic tissues because it is not germline; informed consent alone suffices to permit CRISPR-Cas9 use even in the absence of IRB oversight or formal evidence of causality, provided the procedure could be reversed later.", "solution": "The problem statement is evaluated as valid. It presents a scientifically and ethically realistic scenario involving the application of CRISPR-Cas9 gene editing technology. The givens are self-contained, consistent, and grounded in established principles of molecular biology, genetics, and medical ethics. The problem is well-posed, objective, and requires the integration of multiple domains of knowledge to arrive at a reasoned conclusion.\n\n### Derivation from First Principles\n\nThe core of this problem rests on integrating three areas: $1$) the definition of a genetic Variant of Uncertain Significance ($\\text{VUS}$); $2$) the principles of biomedical ethics; and $3$) the distinction between clinical therapy and human subjects research.\n\n1.  **Genetic Classification:**\n    *   **Variant of Uncertain Significance ($\\text{VUS}$):** According to established frameworks, such as those from the American College of Medical Genetics and Genomics ($\\text{ACMG}$) and the Association for Molecular Pathology ($\\text{AMP}$), a $\\text{VUS}$ is a genetic variant for which the existing evidence is insufficient or conflicting to determine its role in disease. It cannot be confidently classified as either benign or pathogenic. The defining characteristic of a $\\text{VUS}$ is this uncertainty.\n    *   **Pathogenic vs. Likely Pathogenic Variants:** The $\\text{ACMG}$/$\\text{AMP}$ guidelines use a quantitative, evidence-based system. A variant is classified as **Pathogenic** when there is sufficient, convergent evidence to establish causality for a disease (corresponding to a >99% Bayesian probability of pathogenicity). A **Likely Pathogenic** variant has strong evidence of causality, but does not meet the full \"Pathogenic\" criteria (often defined as a >90% probability of pathogenicity). This distinction, while subtle, reflects different levels of certainty. Clinical action may be taken for both, but the underlying evidentiary standard matters.\n    *   **Central Dogma:** The flow of information from deoxyribonucleic acid ($\\text{DNA}$) to ribonucleic acid ($\\text{RNA}$) to protein dictates that a change in the $\\text{DNA}$ sequence (the variant) can lead to an altered protein, which in turn can cause disease (cardiomyopathy). However, for a $\\text{VUS}$, this causal link is unproven.\n\n2.  **Biomedical Ethics:**\n    *   **Nonmaleficence (Do No Harm):** The proposed intervention, somatic CRISPR-Cas9 editing, is not risk-free. It involves creating double-strand breaks in the genome, which carries risks of off-target edits (mutations at unintended sites), on-target errors (e.g., insertions/deletions instead of a precise correction), and risks from the delivery vector. These are real, potential harms.\n    *   **Beneficence (Act in the Patient's Best Interest):** The potential for benefit is entirely dependent on the $\\text{VUS}$ being the actual cause of the patient's heart failure. Since the variant's pathogenicity is uncertain, the benefit is also uncertain. To administer a treatment with real risks for an uncertain benefit violates the balance of beneficence and nonmaleficence.\n    *   **Respect for Autonomy:** The patient's consent is necessary but not sufficient. For consent to be truly informed, the patient must understand the profound uncertainty: the procedure might not help at all (if the $\\text{VUS}$ is benign) and could cause harm.\n    *   **Justice:** This principle requires responsible stewardship of powerful new technologies. Using genome editing outside of a rigorous, evidence-based framework would be an unjust and reckless application.\n\n3.  **Research vs. Clinical Care:**\n    *   **Clinical Care (Therapy):** A therapeutic intervention is justified when there is a reasonable expectation of net benefit for the patient, based on established evidence. Editing a pathogenic variant would fall into this category, as the benefit is clear.\n    *   **Human Subjects Research:** An intervention is experimental, or research, when its safety and/or efficacy are not established. The primary goal of research is to generate generalizable knowledge. To test the hypothesis that \"reverting this $\\text{VUS}$ will ameliorate cardiomyopathy,\" one must conduct a research study. Such studies require strict oversight by an Institutional Review Board ($\\text{IRB}$) to protect the subject, a state of **clinical equipoise** (genuine uncertainty in the expert community), and a rigorous informed consent process.\n\n**Conclusion from Principles:** Editing a $\\text{VUS}$ cannot be considered standard clinical care because the benefit is uncertain. The intervention is, by definition, experimental. Therefore, it may only proceed under a formal research protocol with all accompanying ethical and regulatory safeguards, including $\\text{IRB}$ oversight. For it to become a clinical therapy, the $\\text{VUS}$ would have to be reclassified to at least \"Likely Pathogenic\" based on new evidence, establishing a probable benefit that can be weighed against the procedure's risks.\n\n### Evaluation of Options\n\n**A. A Variant of Uncertain Significance (VUS) is a genetic change with insufficient and conflicting evidence to classify as either benign or pathogenic. A pathogenic variant has sufficient, convergent evidence of causality for disease, whereas a likely pathogenic variant has strong but not definitive evidence, often corresponding to an estimated posterior probability of pathogenicity greater than $90\\%$ under American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) logic. Ethically, editing a VUS as clinical care fails nonmaleficence and beneficence because causal benefit is uncertain and risks from intervention are real; such interventions should proceed only under a research protocol with Institutional Review Board (IRB) oversight, clinical equipoise, rigorous preclinical evidence, and robust informed consent, and should avoid germline editing. In clinical care, somatic CRISPR-Cas9 targeting a VUS is not justified without reclassification to at least likely pathogenic and a favorable risk–benefit profile.**\n\n*   **Analysis:** This option provides a correct definition of a $\\text{VUS}$. It accurately distinguishes between pathogenic and likely pathogenic variants, correctly referencing the $\\text{ACMG}$/$\\text{AMP}$ framework and the probabilistic threshold ($>90\\%$). The ethical reasoning is sound, correctly identifying the failure to meet nonmaleficence and beneficence due to uncertain benefit versus real risk. It correctly identifies the intervention as research, requiring an $\\text{IRB}$-approved protocol, and establishes the proper condition (reclassification of the variant) for it to be considered in a clinical context.\n*   **Verdict:** **Correct**.\n\n**B. A Variant of Uncertain Significance (VUS) is a change that is probably benign, and a likely pathogenic variant is equivalent to a pathogenic variant for clinical decision-making. Because the disease is severe and the patient consents, beneficence and autonomy together justify CRISPR-Cas9 editing of the VUS in routine clinical care without IRB oversight, since off-target risk appears low in animals.**\n\n*   **Analysis:** This option is incorrect on multiple grounds. A $\\text{VUS}$ is not \"probably benign\"; it is uncertain. If it were probably benign, it would be classified as \"likely benign.\" It incorrectly equates autonomy and the severity of disease with a justification for an experimental procedure, ignoring nonmaleficence. It wrongly dismisses the need for $\\text{IRB}$ oversight, which is mandatory for human subjects research.\n*   **Verdict:** **Incorrect**.\n\n**C. A Variant of Uncertain Significance (VUS) is any novel change in a gene plausibly related to a phenotype. Pathogenic and likely pathogenic variants are distinguished by whether the gene is associated with severe disease. In severe disease, beneficence outweighs nonmaleficence, so somatic CRISPR-Cas9 editing of a VUS is ethically permitted if the target gene has a known role in the pathway, regardless of variant-level evidence.**\n\n*   **Analysis:** This option's definition of a $\\text{VUS}$ is too broad and thus incorrect. The distinction between pathogenic and likely pathogenic is based on the strength of evidence for the *variant*, not the severity of the disease. The ethical reasoning is critically flawed; disease severity does not give license to ignore nonmaleficence, especially when benefit is unknown. The core of genetic diagnostics is *variant-level evidence*, which this option incorrectly dismisses.\n*   **Verdict:** **Incorrect**.\n\n**D. A Variant of Uncertain Significance (VUS) is a change that lacks any link to disease but can be treated as likely pathogenic if off-target risks are minimized. Likely pathogenic and pathogenic variants do not meaningfully differ; therefore, editing a VUS is ethically acceptable in clinical care if sequencing depth is high and predicted off-target sites are few.**\n\n*   **Analysis:** This option is fundamentally flawed. A $\\text{VUS}$ has an *uncertain* link to disease, not a *lack* of a link. The classification of a variant is independent of the technical features of the editing tool; minimizing risk does not convert an unknown into a known. The assertion that likely pathogenic and pathogenic do not meaningfully differ is false in the context of evidence-based medicine. Technical quality of the procedure does not address the central ethical problem of uncertain benefit.\n*   **Verdict:** **Incorrect**.\n\n**E. A Variant of Uncertain Significance (VUS) is a genetic change that is uncertain only because the phenotype is mild. Editing a VUS is ethically acceptable in somatic tissues because it is not germline; informed consent alone suffices to permit CRISPR-Cas9 use even in the absence of IRB oversight or formal evidence of causality, provided the procedure could be reversed later.**\n\n*   **Analysis:** This option is incorrect. The uncertainty of a $\\text{VUS}$ does not depend on phenotype severity. The ethical justification is flawed: being somatic and having consent are not sufficient to bypass the need for $\\text{IRB}$ oversight for an experimental procedure. Finally, the claim that CRISPR-Cas9 editing is reversible is factually incorrect; it is a permanent alteration to the genomic $\\text{DNA}$.\n*   **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4858299"}, {"introduction": "Once a gene therapy is proven safe and effective, its final hurdle is societal: is it a just and sustainable use of finite healthcare resources? This exercise introduces you to the tools of health economics, specifically Cost-Effectiveness Analysis and the concept of a Quality-Adjusted Life Year (QALY), which are used to evaluate the financial and social value of new treatments. By analyzing a hypothetical CRISPR therapy's price against its health benefits, you will engage in the kind of evidence-based ethical reasoning that shapes public health policy and ensures equitable access to innovation [@problem_id:4858171].", "problem": "A hospital ethics committee is evaluating whether to adopt a one-time CRISPR-Cas9 therapy for transthyretin amyloidosis in adults. The committee wishes to ground its deliberation in resource-sensitive principles consistent with maximizing aggregate health improvements subject to finite budgets. Using the foundational ethical idea that health states can be represented by a utility weight on the interval $[0,1]$ and aggregated over time to produce a population health measure, define Cost-Effectiveness Analysis (CEA) and the concept of dollars per Quality-Adjusted Life Year (QALY), clarifying how CEA differs in principle from Cost-Benefit Analysis (CBA), which monetizes health outcomes.\n\nAssume the CRISPR therapy has a price of $\\$500{,}000$ and is expected, based on clinical modeling consistent with the Central Dogma of molecular biology and current clinical evidence for amyloid burden reduction, to produce an average gain of $5$ Quality-Adjusted Life Years (QALYs) relative to current care in the target population. Using only the definitions above and first principles of aggregation of health utilities over time, compute the average cost per QALY for the CRISPR therapy. Round your numerical result to four significant figures and express the final ratio in dollars per Quality-Adjusted Life Year (USD/QALY).", "solution": "The problem statement is evaluated as scientifically grounded, well-posed, and objective. It is based on standard, formalizable principles of health economics and medical ethics, specifically Cost-Effectiveness Analysis (CEA) and the concept of Quality-Adjusted Life Years (QALYs). The provided data are sufficient and consistent for the requested calculation. The context involving CRISPR-Cas9 therapy for transthyretin amyloidosis is scientifically plausible and grounded in current biomedical research. Therefore, a solution can be derived.\n\nFirst, we address the conceptual definitions as requested.\n\nThe foundational ethical premise is that health states can be quantified. A Quality-Adjusted Life Year (QALY) is a unit of measure that combines both the quantity (length) and the quality of life. For a given period of time, the number of QALYs is the product of the duration of time in a particular health state and a utility weight assigned to that health state. Utility weights are on a continuous scale from $0$ to $1$, where $1$ represents a state of perfect health and $0$ represents a state equivalent to death. If an individual lives for $T$ years with a health-related quality of life represented by a utility function $u(t)$, where $u(t) \\in [0, 1]$, the total QALYs experienced over that period is given by the integral:\n$$ \\text{QALYs} = \\int_{0}^{T} u(t) \\, dt $$\nFor a simplified model with discrete time periods, where an individual spends $t_i$ years in a health state with a constant utility weight $u_i$, the total QALYs are the sum:\n$$ \\text{QALYs} = \\sum_{i} u_i \\cdot t_i $$\n\nCost-Effectiveness Analysis (CEA) is an economic evaluation framework used to compare the relative value of different health interventions. It assesses an intervention by relating its costs to the health benefits it produces. In CEA, costs are measured in monetary units (e.g., dollars), while health benefits are measured in natural health units, such as life-years gained, cases prevented, or, most comprehensively, QALYs gained. The primary outcome of a CEA is the Cost-Effectiveness Ratio (CER), often expressed as the Incremental Cost-Effectiveness Ratio (ICER). The ICER compares a new intervention (let's call it $A$) to a standard or current care option (let's call it $B$). It is calculated as the ratio of the difference in costs to the difference in health effects:\n$$ \\text{ICER} = \\frac{\\Delta C}{\\Delta E} = \\frac{\\text{Cost}_A - \\text{Cost}_B}{\\text{Effect}_A - \\text{Effect}_B} $$\nThe term \"dollars per QALY\" is the unit of the ICER when costs ($\\Delta C$) are measured in dollars and effects ($\\Delta E$) are measured in QALYs. It represents the additional cost incurred to gain one additional QALY.\n\nThe principal distinction between Cost-Effectiveness Analysis (CEA) and Cost-Benefit Analysis (CBA) lies in the valuation of health outcomes. In CEA, health outcomes (effects, $E$) are maintained in their non-monetary, health-specific units (like QALYs), resulting in a ratio as the final output. In contrast, CBA converts all aspects of an intervention, including health benefits, into monetary terms. This requires assigning a direct dollar value to outcomes like a year of life or a QALY gained (the \"willingness-to-pay\" for a QALY). The final output of a CBA is a net monetary value (Benefits $-$ Costs) or a benefit-cost ratio (Benefits / Costs). CEA avoids the explicit monetization of life and health, a step that is often ethically controversial and methodologically challenging.\n\nNext, we proceed with the calculation based on the provided data. The problem asks for the average cost per QALY for the CRISPR therapy. This is an application of the ICER formula, where the comparator is the \"current care\".\n\nThe incremental cost, $\\Delta C$, is the additional cost of the CRISPR therapy compared to current care. The problem gives the price of the therapy as $\\$500,000$. We can assume this is the net additional cost.\n$$ \\Delta C = 500,000 \\text{ USD} $$\nThe incremental health effect, $\\Delta E$, is the average gain in QALYs provided by the therapy relative to current care. The problem states this is $5$ QALYs.\n$$ \\Delta E = 5 \\text{ QALYs} $$\nThe average cost per QALY is the ratio of the incremental cost to the incremental QALYs gained:\n$$ \\text{Cost per QALY} = \\frac{\\Delta C}{\\Delta E} $$\nSubstituting the given values:\n$$ \\text{Cost per QALY} = \\frac{500,000}{5} \\frac{\\text{USD}}{\\text{QALY}} $$\nPerforming the division:\n$$ \\text{Cost per QALY} = 100,000 \\frac{\\text{USD}}{\\text{QALY}} $$\nThe problem requires the numerical result to be rounded to four significant figures. The calculated value is exactly $100,000$. To express this with four significant figures, we write it in scientific notation as $1.000 \\times 10^5$.", "answer": "$$\\boxed{1.000 \\times 10^5}$$", "id": "4858171"}]}